In yesterday’s Wall Street session, Co-Diagnostics Inc. (NASDAQ:CODX) shares traded at $2.52, down -0.40% from the previous session.
CODX stock price is now -18.45% away from the 50-day moving average and -42.90% away from the 200-day moving average. The market capitalization of the company currently stands at $78.20M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
With the price target maintained at $5, Sidoti recently Downgraded its rating from Buy to Neutral for Co-Diagnostics Inc. (NASDAQ: CODX). On December 29, 2021, Sidoti recently initiated its ‘Buy’ rating on the stock quoting a target price of $14, while ‘Maxim Group’ rates the stock as ‘Hold’.
Insiders disposed of 70,020 shares of company stock worth roughly $0.18 million over the past 1 year. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CODX stock. A new stake in Co-Diagnostics Inc. shares was purchased by WALLEYE CAPITAL LLC during the first quarter worth $346,000. TOWNSQUARE CAPITAL LLC invested $169,000 in shares of CODX during the first quarter. In the first quarter, CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. acquired a new stake in Co-Diagnostics Inc. valued at approximately $164,000. ENGINEERS GATE MANAGER LP acquired a new stake in CODX for approximately $127,000. TOWER RESEARCH CAPITAL LLC (TRC) purchased a new stake in CODX valued at around $73,000 in the second quarter. In total, there are 86 active investors with 21.00% ownership of the company’s stock.
On Friday morning Co-Diagnostics Inc. (NASDAQ: CODX) stock kicked off with the opening price of $2.4800. During the past 12 months, Co-Diagnostics Inc. has had a low of $2.26 and a high of $10.11. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 17.00, and a quick ratio of 16.00. The fifty day moving average price for CODX is $3.0784 and a two-hundred day moving average price translates $4.3952 for the stock.
The latest earnings results from Co-Diagnostics Inc. (NASDAQ: CODX) was released for Sep, 2022. According to the Diagnostics & Research Company, earnings per share came in at -$0.08, missing analysts’ expectations of $0.1 by -0.18. This compares to $0.38 EPS in the same period last year. The net profit margin was 28.50% and return on equity was 10.80% for CODX. The company reported revenue of $5.09 million for the quarter, compared to $30.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -83.07 percent. For the current quarter, analysts expect CODX to generate $7.98M in revenue.
Co-Diagnostics Inc.(CODX) Company Profile
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
